Advanced search
Publication Cover
Postgraduate Medicine Volume 129, 2017 - Issue 6
Submit an article Journal homepage
103
Views
4
CrossRef citations to date
0
Altmetric
Clinical Features - Original Research

Diagnostic performance of CTLA-4, carcinoembryonic antigen and CYFRA 21-1 for malignant pleural effusion

Mei ChenDepartment of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, ChinaView further author information
,
Shenglong XieDepartment of Thoracic Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, ChinaView further author information
,
Chun WanDepartment of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, ChinaView further author information
,
Ni ZengDepartment of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, ChinaView further author information
,
Yanqiu WuDepartment of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, ChinaView further author information
,
Jiangyue QinDepartment of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, ChinaView further author information
,
Yongchun ShenDepartment of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, ChinaCorrespondence[email protected] [email protected]
View further author information
&
Fuqiang WenDepartment of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University and Division of Pulmonary Diseases, State Key Laboratory of Biotherapy of China, Chengdu, ChinaView further author information
 show all
Pages 644-648 | Received 01 Feb 2017, Accepted 12 May 2017, Published online: 19 May 2017

References

  • Azzopardi M, Porcel JM, Koegelenberg CF, et al. Current controversies in the management of malignant pleural effusions. Semi Respir Crit Care Med. 2014;35:723–731.
  • Morgensztern D, Waqar S, Subramanian J, et al. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7:1485–1489.
  • Office of National Statistics, Stationary Office. Cancer statistics registrations, England. 2010. (Series MB1).
  • Roberts ME, Neville E, Berrisford RG, et al. BTS pleural disease guideline group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(Suppl 2):ii32–40.
  • Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc. 1985;60:158–164.
  • Rakha EA, Patil S, Abdulla K, et al. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol. 2010;38:874–879.
  • Skalski JH, Astoul PJ, Maldonado F. Medical thoracoscopy. Semin Respir Crit Care Med. 2014;35:732–743.
  • Koegelenberg CF, Diacon AH. Image-guided pleural biopsy. Curr Opin Pulm Med. 2013;19:368–373.
  • Shen YC, Liu MQ, Wan C, et al. Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion. Exp Ther Med. 2012;3:1072–1076.
  • Shi HZ, Liang QL, Jiang J, et al. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology. 2008;13:518–527.
  • Nguyen AH, Miller EJ, Wichman CS, et al. Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis. Transl Res. 2015;166:432–439.
  • Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94:25–39.
  • Mocellin S, Nitti D. CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochim Biophys Acta. 2013;1836:187–196.
  • Zhang Y, Zhang J, Deng Y, et al. Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and cancer risk: a meta-analysis. Cancer. 2011;117:4312–4324.
  • Antczak A, Pastuszak-Lewandoska D, Górski P, et al. Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer. Biomed Res Int. 2013;2013:1–8.
  • Roncella S, Laurent S, Fontana V, et al. CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor. Cancer Immunol Immunother. 2016;65:909–917.
  • Mao H, Zhang L, Yang Y, et al. New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets. 2010;10:728–736.
  • Creaney J, Yeoman D, Musk AW, et al. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma – which is best? Lung Cancer. 2011;74(1):55–60.
  • Akulian J, Feller-Kopman D. The past, current and future of diagnosis and management of pleural disease. J Thorac Dis. 2015;7:S329–38.
  • Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015;125:3377–3383.
  • Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98–106.
  • Shen Y, Pang C, Shen K, et al. Diagnostic value of thyroid transcription factor-1 for pleural or other serous metastases of pulmonary adenocarcinoma: a meta-analysis. Sci Rep. 2016;6:19785.
  • Salama AK, Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res. 2011;17:4622–4628.
  • Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322:271–275.
  • Tian P, Shen Y, Feng M, et al. Diagnostic accuracy of endostatin for malignant pleural effusion: a clinical study and meta-analysis. Postgrad Med. 2015;127(5):529–534.
  • Gu Y, Zhai K, Shi HZ. Clinical value of tumor markers for determining cause of pleural effusion. Chin Med J (Engl). 2016;129:253–258.
  • Son SM, Han HS, An JY, et al. Diagnostic performance of CD66c in lung adenocarcinoma-associated malignant pleural effusion: comparison with CEA, CA 19-9, and CYFRA 21-1. Pathology. 2015;47:123–129.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.